An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jun 2024 According to Lundbeck media release, company announced data presentations of this trial at the 66th Annual Scientific Meeting of the American Headache Society (AHS) taking place in San Diego, Calif., June 13-16, 2024
19 Jun 2023 According to Lundbeck Inc media release, data from this study will be presented at the 65th Annual Scientific Meeting of the American Headache Society (AHS)
28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com